

Tina Kotek, Governor

OFFICIAL WEBSITE NOTICE
Posting Date: August 13, 2025

**OREGON HEALTH AUTHORITY DIRECTOR'S DECISION ON
PHARMACY AND THERAPEUTICS COMMITTEE RECOMMENDATIONS
DATED AUGUST 13, 2025**

I have reviewed the recommendations of the Pharmacy and Therapeutics Committee set out below and have reviewed a staff memo dated Aug. 11, 2025. Based on my review:

The recommendations of the Pharmacy and Therapeutics Committee are approved.

Recommendations with respect to the inclusion of a drug on the Oregon Practitioner-Managed Prescription Drug Plan will be put into place no earlier than 7 days from the date this notice is posted on the website.



Sejal Hathi, MD, MBA
Director

8/13/2025
Approval date

A request for reconsideration of this decision to adopt the recommendations of the Drug Use Review / Pharmacy and Therapeutics Committee must be filed with and received by the Director no later than 7 calendar days from the date of this notice. ORS 414.361(6)(b).

RECOMMENDATIONS OF DRUG USE REVIEW / PHARMACY AND THERAPEUTICS COMMITTEE

The Oregon Drug Use Review / Pharmacy and Therapeutics Committee met virtually on Thursday, Aug. 7, 2025. The Committee considered in order of priority: the safety and efficacy of the drugs being considered; the ability of Oregonians to access effective prescription drugs that are appropriate for their clinical conditions; and substantial differences in costs of drugs within the same therapeutic class. Based upon the clinical information presented by staff ⁱ and all public comment offered,ⁱⁱ while considering the impact on people, populations and communities who have been most impacted by historic and contemporary injustices and health inequities including but not limited to Oregon Tribal Nations, American Indian or Alaska Native persons, Hispanic, Latino, Latina, or Latinx persons, Black or African American persons, Asian or Asian American persons, Pacific Islander or Native Hawaiian persons, people with disabilities, people with limited English proficiency, and immigrants and refugees, the Committee makes the following recommendations for Drug Use Review, the Oregon Practitioner-Managed Prescription Drug Plan (PMPDP), or for any other preferred drug list established by the Oregon Health Authority:

Buprenorphine Policy Evaluation

Based on the review of utilization patterns of buprenorphine products since raising the quantity limit from 24 mg per day to 32 mg per day in August 2023, the Committee recommended making no changes to the policy or Buprenorphine and Buprenorphine/Naloxone Prior Authorization (PA) criteria.

Oncology Policy Updates

The Committee recommended adding the following antineoplastic agents recently approved by the U.S. Food and Drug Administration (FDA) to Table 1 in the Oncology Agents PA criteria: Avmapki™ Fakzynja™ Co-Pack (avutometinib and defactinib); Lynozyfic™ (ivoseltamab-gcpt); Penpulimab-kcq; Zegfrovy™ (sunvozertinib); Ibtrozi™ (taletrectinib); Emrelis™ (telisotuzumab vedotin-tllv); and Grafapex™ (treosulfan).

Orphan Drug Policy Updates

The Committee recommended updating Table 1 in the Orphan Drugs PA criteria to support medically appropriate use of: Imaavy™ (nipocalimab-aahu); and Rezzayo® (rezafungin).

Gene Therapy for Sickle Cell Disease

The Committee recommended making Casgevy® (exagamglogene autotemcel) and Lyfgenia™ (lovotibeglogene autotemcel) preferred on the PMPDP and to modify the Gene Therapies for Sickle Cell Disease PA criteria to allow the state to participate in the Cell and Gene Therapy Access Model for sickle cell disease gene therapies. The Committee also recommended discontinuing the Lovotibeglogene Autotemcel PA criteria.

DRUG	CHANGE
exagamglogene autotemcel	Make preferred on the PMPDP
lovotibeglogene autotemcel	Make preferred on the PMPDP

Second-generation Antipsychotics Class Update and New Drug Evaluation

The Committee recommended making no changes to the PMPDP for the First-Generation Antipsychotics, Second-Generation Antipsychotics or Parenteral antipsychotics based on review of recent clinical evidence. After comparative cost consideration in the executive session, the Committee recommended making no changes to the PMPDP.

Modafinil and Armodafinil Drug Use Evaluation

The Committee recommended automatically approving requests for modafinil or armodafinil for members with narcolepsy when prescribed for daily doses at or below 200 mg for modafinil or 250 mg for armodafinil, but continue to require PA for other indications and for higher doses. The Committee also recommended updating the Sleep-Wake Medications PA criteria to approve higher doses of modafinil when lower doses are only partially effective.

Hepatitis B Antivirals Class Update

The Committee recommended making entecavir tablets preferred on the PMPDP based on recent guidelines and to make lamivudine non-preferred due to viral resistance patterns. The Committee recommended revising the Hepatitis B Antivirals PA criteria to only apply to non-preferred agents. After comparative cost consideration in executive session, the Committee recommended making no changes to the PMPDP.

New Antibiotics for Urinary Tract Infections

The Committee recommended making no changes to PMPDP for the new drugs for uncomplicated urinary tract infections based on review of the clinical evidence and to maintain Orlynvah™ (sulopenem/probenecid), Pivya™ (pivmecillinam) and Blujepa (gepotidacin) as non-preferred.

Vykat™ XR (diazoxide choline) New Drug Evaluation

The Committee recommended making Vykat™ XR (diazoxide choline) extended-release tablets non-preferred on the PMPDP and to implement the Diazoxide Choline Extended-Release Tablets PA criteria to ensure appropriate use in patients with hyperphagia due to Prader-Willi syndrome.

DRUG	CHANGE
diazoxide choline	Make non-preferred on the PMPDP

The Committee has made these recommendations to the Oregon Health Authority for approval by the Director of the Oregon Health Authority or their designee.

ⁱ https://www.orphdl.org/durm/meetings/meetingdocs/2025_08_07/finals/2025_08_07_PnT_Complete.pdf

ⁱⁱ https://www.orphdl.org/durm/meetings/meetingdocs/2025_08_07/finals/2025_08_07_WrittenTestimony.pdf